Molecular Evaluation of Colorectal Adenocarcinoma: Current Practice and Emerging Concepts

Surgical Pathology Clinics

Volumn 9, Issue 3, 2016, Pages 427-439

  Nowak, Jonathan A ^a   Hornick, Jason L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Colorectal cancer; EGFR pathway; Immune checkpoint blockade; Lynch syndrome; Microsatellite instability; Mismatch repair; PD L1; Targeted therapy

Indexed keywords

PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; B RAF KINASE;

CANCER PROGNOSIS; CLINICAL PRACTICE; COLORECTAL CARCINOMA; DNA SEQUENCE; GENE; GENE DELETION; GENE INSERTION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MEDICAL DECISION MAKING; METASTATIC COLORECTAL CANCER; MISMATCH REPAIR; MISSENSE MUTATION; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; MSH2 GENE; PATHOGENESIS; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; ADENOCARCINOMA; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; GENETICS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROMOTER REGION; TRENDS;

ADENOCARCINOMA; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84981225792     PISSN: 18759181     EISSN: 18759157     Source Type: Journal    
DOI: 10.1016/j.path.2016.04.007     Document Type: Review

References (48)

1. 1 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J Clin 65:1 (2015), 5–29.
2. 2 Fearon, E.R., Vogelstein, B., A genetic model for colorectal tumorigenesis. Cell 61:5 (1990), 759–767.
3. 3 Vogelstein, B., Fearon, E.R., Hamilton, S.R., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 319:9 (1988), 525–532.
4. 4 Cancer Genome Atlas Network, Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:7407 (2012), 330–337.
5. 5 Grady, W.M., Markowitz, S.D., The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening. Dig Dis Sci 60:3 (2015), 762–772.
6. 6 Giardiello, F.M., Allen, J.I., Axilbund, J.E., et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol 109:8 (2014), 1159–1179.
7. 7 Tiwari, A.K., Roy, H.K., Lynch, H.T., Lynch syndrome in the 21st century: clinical perspectives. QJM 109:3 (2016), 151–158.
8. 8 Wimmer, K., Etzler, J., Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?. Hum Genet 124:2 (2008), 105–122.
9. 9 Durno, C.A., Holter, S., Sherman, P.M., et al. The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations. Am J Gastroenterol 105:11 (2010), 2449–2456.
10. 10 Vasen, H.F., Watson, P., Mecklin, J.P., et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:6 (1999), 1453–1456.
11. 11 Umar, A., Boland, C.R., Terdiman, J.P., et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:4 (2004), 261–268.
12. 12 Evaluation of Genomic Applications in Practice and Prevention Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11:1 (2009), 35–41.
13. 13 Cicek, M.S., Lindor, N.M., Gallinger, S., et al. Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn 13:3 (2011), 271–281.
14. 14 Murphy, K.M., Zhang, S., Geiger, T., et al. Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn 8:3 (2006), 305–311.
15. 15 Weisenberger, D.J., Siegmund, K.D., Campan, M., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:7 (2006), 787–793.
16. 16 Deng, G., Bell, I., Crawley, S., et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10:1 Pt 1 (2004), 191–195.
17. 17 Yurgelun, M.B., Goel, A., Hornick, J.L., et al. Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res 5:4 (2012), 574–582.
18. 18 Gryfe, R., Kim, H., Hsieh, E.T., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342:2 (2000), 69–77.
19. 19 Guastadisegni, C., Colafranceschi, M., Ottini, L., et al. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer 46:15 (2010), 2788–2798.
20. 20 Sargent, D.J., Marsoni, S., Monges, G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:20 (2010), 3219–3226.
21. 21 Ribic, C.M., Sargent, D.J., Moore, M.J., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:3 (2003), 247–257.
22. 22 Lasry, A., Zinger, A., Ben-Neriah, Y., Inflammatory networks underlying colorectal cancer. Nat Immunol 17:3 (2016), 230–240.
23. 23 Le, D.T., Uram, J.N., Wang, H., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:26 (2015), 2509–2520.
24. 24 Herbst, R.S., Soria, J.C., Kowanetz, M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:7528 (2014), 563–567.
25. 25 Taube, J.M., Klein, A., Brahmer, J.R., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:19 (2014), 5064–5074.
26. 26 Hebbar, M., Wacrenier, A., Desauw, C., et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 17:7 (2006), 855–857.
27. 27 Van Cutsem, E., Kohne, C.H., Hitre, E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:14 (2009), 1408–1417.
28. 28 Tol, J., Koopman, M., Cats, A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:6 (2009), 563–572.
29. 29 Therkildsen, C., Bergmann, T.K., Henrichsen-Schnack, T., et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 53:7 (2014), 852–864.
30. 30 De Roock, W., Claes, B., Bernasconi, D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet 11:8 (2010), 753–762.
31. 31 Pietrantonio, F., Petrelli, F., Coinu, A., et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 51:5 (2015), 587–594.
32. 32 Bokemeyer, C., Van Cutsem, E., Rougier, P., et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48:10 (2012), 1466–1475.
33. 33 Rowland, A., Dias, M.M., Wiese, M.D., et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 112:12 (2015), 1888–1894.
34. 34 Lochhead, P., Kuchiba, A., Imamura, Y., et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 105:15 (2013), 1151–1156.
35. 35 Russo, A.L., Borger, D.R., Szymonifka, J., et al. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer 120:10 (2014), 1482–1490.
36. 36 Temraz, S., Alameddine, R., Shamseddine, A., B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches. Curr Opin Oncol 27:3 (2015), 276–281.
37. 37 Liao, X., Morikawa, T., Lochhead, P., et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 18:8 (2012), 2257–2268.
38. 38 Mao, C., Yang, Z.Y., Hu, X.F., et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 23:6 (2012), 1518–1525.
39. 39 Paleari, L., Puntoni, M., Clavarezza, M., et al. PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. A systematic review and meta-analysis of epidemiological studies. Clin Oncol 28:5 (2016), 317–326.
40. 40 Liao, X., Lochhead, P., Nishihara, R., et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367:17 (2012), 1596–1606.
41. 41 Lin, P.C., Lin, J.K., Lin, H.H., et al. A comprehensive analysis of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) loss in colorectal cancer. World J Surg Oncol, 13, 2015, 186.
42. 42 Jang, K.S., Song, Y.S., Jang, S.H., et al. Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology 56:2 (2010), 229–239.
43. 43 Sadanandam, A., Wang, X., de Sousa, E.M.F., et al. Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications. Cell Cycle 13:3 (2014), 353–357.
44. 44 Ogino, S., Chan, A.T., Fuchs, C.S., et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 60:3 (2011), 397–411.
45. 45 Imamura, Y., Morikawa, T., Liao, X., et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res 18:17 (2012), 4753–4763.
46. 46 Siyar Ekinci, A., Demirci, U., Cakmak Oksuzoglu, B., et al. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma. J BUON 20:1 (2015), 128–135.
47. 47 Dono, M., Massucco, C., Chiara, S., et al. Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer. Mol Med 18 (2012), 1519–1526.
48. 48 Italiano, A., Hostein, I., Soubeyran, I., et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 17:5 (2010), 1429–1434.